SEC Form 4 · accession 0001232524-16-000196
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seamus Mulligan
Director
Period of report
Feb 23, 2016
Accepted (ET)
Feb 24, 2016 · 7:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Feb 23, 2016 | S | 2,716 | $120.678 | D | 1,127,831 | D | |
| Ordinary SharesF3 | Feb 23, 2016 | S | 4,779 | $122.0285 | D | 1,123,052 | D | |
| Ordinary SharesF4 | Feb 23, 2016 | S | 15,824 | $122.8327 | D | 1,107,228 | D | |
| Ordinary SharesF5 | Feb 23, 2016 | S | 2,927 | $123.8117 | D | 1,104,301 | D | |
| Ordinary SharesF6 | Feb 23, 2016 | S | 1,722 | $124.7776 | D | 1,102,579 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $120.2000 to $121.1900. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $121.2387 to $122.2200. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $122.3300 to $123.3100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $123.3900 to $124.3000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $124.3900 to $125.3000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.